BIM
IONS icon

Bogle Investment Management’s Ionis Pharmaceuticals IONS Stock Holding History

Bogle Investment Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-16,600
Closed -$841K – 313
2017
Q3 		$841K Buy
+16,600
New +$870K 0.06% 247
2016
Q3 		– Sell
-576,970
Closed -$13.4M – 398
2016
Q2 		$13.4M Buy
+576,970
New +$18.6M 0.93% 12
2014
Q1 		– Sell
-95,088
Closed -$3.79M – 373
2013
Q4 		$3.79M Sell
95,088
-125,303
-57% -$4.46M 0.32% 110
2013
Q3 		$8.27M Sell
220,391
-74,216
-25% -$2.22M 0.84% 28
2013
Q2 		$7.92M Buy
+294,607
New +$6.26M 0.97% 12

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Bogle Investment Management's IONS Position: Q4 2017 in Review

Bogle Investment Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2017, closing a stake of 16,600 shares — an estimated $841K sold.

Bogle Investment Management first reported a position in IONS in Q2 2013 and held it in 5 quarters. The position peaked at $13.4M in Q2 2016. 316 funds tracked by Wall St. Rank hold IONS as of Q4 2017.

  • Bogle Investment Management reported no remaining Ionis Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Bogle Investment Management sold 16,600 Ionis Pharmaceuticals shares in Q4 2017, an estimated $841K.
  • Bogle Investment Management first reported a position in Ionis Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Bogle Investment Management's Ionis Pharmaceuticals position peaked at $13.4M in Q2 2016.
  • 316 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2017.

Based on Bogle Investment Management's 13F filing for Q4 2017, filed 13 Feb 2018.